Skip to main content
. 2011 Aug 17;118(18):4817–4828. doi: 10.1182/blood-2011-04-348540

Table 6.

Summary of patient responses

Patient ID Response to T-cell infusions
CLL-1 No objective response
CLL-2 No objective response
CLL-3 No objective response
CLL-4 Not evaluable
CLL-5 Marked reduction in lymphadenopathy at 3 months, subsequently stable for 6 months
CLL-6 Progressive disease
CLL-7 Stable disease, lasting 4 months
CLL-8 Stable disease, lasting > 8 weeks
ALL-1 Persistent B-cell aplasia in BM and peripheral blood